Software businesses where the metric is qualified pipeline, not sign-ups.
Trials are easy to buy and expensive to convert. Growth comes from the narrow band of users who reach value quickly.
Media and content optimised to sales-qualified opportunities.
Being clearly one thing, because a vague product is an expensive one to market.
Documentation and use cases that rank and also reduce churn.
Onboarding and activation sequences owned as marketing, not left to product alone.
We work with premium and considered-purchase brands, which is broader than luxury. The common factor is that the buyer researches carefully and is willing to pay more for confidence, rather than looking for the cheapest option.
Often yes, and we will tell you plainly if not. The categories listed are where we have the most pattern recognition, but the underlying discipline transfers to most considered-purchase businesses.
Not within the same category and market. Exclusivity in your segment is part of the arrangement, which is one reason we take on a limited number of clients.
Because the tactic changes even when the principle does not. A dental practice is won in local search; a jewellery house is won over a six-month consideration cycle. Generic retainers charge you for the average of every category.
Yes. In health, pharma, finance and legal we work within advertising and claims rules from the outset, and we would rather lose a campaign idea than a licence.
Yes. Market entry usually begins with the diagnosis extended to cover the new territory: demand, competitors, search behaviour and what the brand can credibly claim there.
The first two weeks are spent doing exactly that. In a category we already know, the diagnosis is faster and sharper, which is the practical benefit of a narrow client list.
Tell us the situation and we will say what we would do first, including the parts you could reasonably do yourselves.